Outcomes remain highly uncertain and hinge on uptake, effectiveness, persistency, and any benefits beyond BMI reduction so insurers should monitor this fast-moving landscape and consider implications for trend assumptions, lapse/anti-selection risk, underwriting, and claims
Many research programs evaluate both individual compounds and blend-based materials
Its your biology pushing back
I am still waiting to see a reduction on the pigmentation spots Started this to help with my mood, anxiety/depression, as well as having many autoimmune issues which got worse since COVID
Neither Noom nor Medvi currently integrate genetic pathway assessment into personalization
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study